Urologists, NFL launch prostate cancer awareness effort

Share this article:
Urologists, NFL launch prostate cancer awareness effort
Urologists, NFL launch prostate cancer awareness effort
The American Urological Association is partnering with the NFL for a GlaxoSmithKline-supported prostate cancer awareness campaign with the message that men should start getting tested at age 40.

The “Know Your Stats About Prostate Cancer” campaign includes print and broadcast PSAs featuring 27 retired NFL Hall of Famers, including prostate cancer survivor Michael Haynes, diagnosed with the disease last year through a free NFL Player Care Foundation screening conducted by the AUA Foundation.

One in six men will be diagnosed with the disease and African-American men like Haynes are twice as likely to die from the disease. Haynes, 56, made his name playing cornerback with the Patriots and the Raiders.

The campaign, which launched in September and is set to run through March, also features a website, KnowYourStats.org. Zeno Group holds the PR assignment for the effort, while Boston Group handled the ads.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...